Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial
Journal of Affective Disorders · 2026-06 · 403 · 121423
DOI: 10.1016/j.jad.2026.121423 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Affective Disorders, 2026-06. Verfasst von Marc J Weintraub und 13 weiteren Autor:innen. Beteiligte Einrichtung: UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, United States of Am…. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Major Depressive Disorder, Psilocybin, Hallucinogens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCCIH NIH HHS, National Center for Complementary and Integrative Health, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Psilocybin-assisted therapy has emerged as a promising treatment for major depressive disorder, but little attention has been paid to the psychotherapy that adjoins psilocybin. Providing an adjunctive psychotherapy that is manualized and evidence-based may make psilocybin treatment more acceptable, effective, and disseminable. We examined the acceptability, feasibility, and clinical outcomes of psilocybin paired with cognitive behavioral therapy (CBT) for major depressive disorder. METHODS: Participants were adults with major depressive disorder who presented with at least moderately severe depressive symptoms. All participants underwent psilocybin-assisted CBT (PA-CBT), which consisted of two psilocybin doses (10 mg and 25 mg separated by one month) interspersed with 12 psychotherapy sessions over four months. Participants' depressive symptoms, psychosocial functioning, and cognitive-affective responses were collected at the study's baseline, at the completion of PA-CBT, and three months post-treatment. RESULTS: Sixteen participants were enrolled, and all were retained through the 7-month study. PA-CBT was rated as highly acceptable by participants and study clinicians, with no serious adverse events reported. Based on independent assessments, 13 of 16 participants showed at least moderate (≥ 25%) improvement in depressive symptoms by the end of treatment, and 9 had fully remitted. Pre-to-post treatment improvements in depressive symptoms and psychosocial functioning were sustained at the 3-month follow-up (Hedges' gs = 1.9-2.7). Changes in depressive severity during the treatment were associated with improvements in emotion regulation and positive and negative cognitive schemas. CONCLUSIONS: CBT appears to be a feasible, well-accepted, and beneficial adjunct to psilocybin treatment. Future randomized trials are needed to compare the efficacy of PA-CBT with other psilocybin-assisted therapy modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, United States of America. Electronic address: mjweintraub@mednet.ucla.edu.
- UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, United States of America.
- UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, United States of America; The Lunquist Institute for BioMedical Innovation at Harbor-UCLA…
Förderung
- NCCIH NIH HHS
- National Center for Complementary and Integrative Health
- National Institutes of Health
- California Community Foundation
- Brain and Behavior Research Foundation
Zitieren
APA
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C., Bergman, R. L., Shapiro, B., Barnett, G., Artin, H., Lynn, M., Salimian, A., Grody, S., Ramesh, R., Eales, L., Grob, C. S., & Miklowitz, D. J. (2026). Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial. Journal of Affective Disorders, 403, 121423. https://doi.org/10.1016/j.jad.2026.121423
Vancouver
Weintraub MJ, Jeffrey JK, Ichinose MC, Bergman RL, Shapiro B, Barnett G, et al. Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial. Journal of Affective Disorders. 2026;403:121423. doi:10.1016/j.jad.2026.121423
BibTeX
@article{Weintraub2026,
author = {Weintraub, Marc J and Jeffrey, Jessica K and Ichinose, Megan C and Bergman, R Lindsey and Shapiro, Benjamin and Barnett, Gregory and Artin, Hewa and Lynn, Marc and Salimian, Anabel and Grody, Shelby and Ramesh, Rahul and Eales, Lauren and Grob, Charles S and Miklowitz, David J},
title = {Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {403},
pages = {121423},
doi = {10.1016/j.jad.2026.121423}
}
EUVIMED